|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Net revenues | |||||
| Cost of sales | |||||
| Gross Profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Interest income | |||||
| Interest and finance expenses | |||||
| Loss from investment | |||||
| Unrealized gain (loss) from investment | |||||
| Total other income (expense) | |||||
| Loss before provision for taxes | |||||
| Provision (benefit) for income taxes: | |||||
| Current | |||||
| Deferred | |||||
| Total benefit (provision) for income taxes | |||||
| Net loss | |||||
| Basic and diluted loss per common share: (in dollars per share) | |||||
| Weighted average shares of common stock outstanding - basic and diluted (in shares) | |||||
Loading...